Johnson & Johnson crushed earnings expectations and raised its guidance for the year
Flickr
The pharmaceutical giant posted revenues of $18.5 billion, up 3.9% year-on-year, and more than analysts' median forecast for $18 billion according to Bloomberg.
Adjusted earnings per share came in at $1.74 ($1.68 expected.)
"We saw notable strength in our Pharmaceuticals business due to the continued success of new products, and also achieved significant clinical milestones, advancing our robust pipeline," said CEO Alex Gorsky in the earnings statement.
The company raised its sales guidance for the full year to $72.2 billion from $71.5 billion. It boosted its EPS expectation to $6.63 - $6.73 per share.
Global pharmaceutical sales rose 8.9% to $8.7 billion, driven by new products like Imbruvica, a lymph node cancer treatment, and Invokana, which treats type 2 diabetes.
Johnson & Johnson shares rose as much as 3% in premarket trading.
- US buys 81 Soviet-era combat aircraft from Russia's ally costing on average less than $20,000 each, report says
- 2 states where home prices are falling because there are too many houses and not enough buyers
- A couple accidentally shipped their cat in an Amazon return package. It arrived safely 6 days later, hundreds of miles away.
- 9 health benefits of drinking sugarcane juice in summer
- 10 benefits of incorporating almond oil into your daily diet
- From heart health to detoxification: 10 reasons to eat beetroot
- Why did a NASA spacecraft suddenly start talking gibberish after more than 45 years of operation? What fixed it?
- ICICI Bank shares climb nearly 5% after Q4 earnings; mcap soars by ₹36,555.4 crore